Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease

References

• O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–8. doi:10.1016/s0140-6736(09)61204-6.
   PubMed Web of Science ®Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Luksic I, Nair H, McAllister DA, Campbell H, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018;6(7):e744–e757. doi:10.1016/s2214-109x(18)30247-x.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019. Wkly Epidemiol Rec. 2019;94(8):85–104.
   Google Scholar
• Ganaie F, Saad JS, McGee L, van Tonder AJ, Bentley SD, Lo SW, Gladstone RA, Turner P, Keenan JD, Breiman RF, et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus. mBio. 2020;11(3):e00937–00920. doi:10.1128/mBio.00937-20.
   PubMed Web of Science ®Google Scholar
• Cherian T. WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26-27 October 2006, Geneva. Vaccine. 2007;25(36):6557–64. doi:10.1016/j.vaccine.2007.06.044.
   PubMedGoogle Scholar
• Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30(1):122–40. doi:10.1086/313609.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30(1):100–21. doi:10.1086/313608.
   PubMed Web of Science ®Google Scholar
• Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, Muenz LR, O’Brien KL. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10):e1000348. doi:10.1371/journal.pmed.1000348.
   PubMed Web of Science ®Google Scholar
• Cohen O, Knoll M, O’Brien K, Ramakrishnan M, Constenla D, Privor-Dumm L, Buss-Younkin J, Farrar J, Pilishvili T, Whitney C, et al. Pneumococcal conjugate vaccine (PCV) product assessment. 2017 [accessed 2020 June 3]. https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/pcv-product-assessment-april-25-2017.pdf.
   Google Scholar
• Poolman JT, Peeters CC, van den Dobbelsteen GP. The history of pneumococcal conjugate vaccine development: dose selection. Expert Rev Vaccines. 2013;12(12):1379–94. doi:10.1586/14760584.2013.852475.
   PubMed Web of Science ®Google Scholar
• de Oliveira LH, Camacho LA, Coutinho ES, Martinez-Silveira MS, Carvalho AF, Ruiz-Matus C, Toscano CM. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American countries: a systematic review. PLoS One. 2016;11(12):e0166736. doi:10.1371/journal.pone.0166736.
   PubMed Web of Science ®Google Scholar
• Cohen O, Knoll M, O’Brien K, Ramakrishnan M, Farrar J, Pilishvili T, Whitney C, Goldblatt D, Moisi J, de Cola M, et al. Pneumococcal conjugate vaccine (PCV) review of impact evidence (PRIME): summary of findings from systematic review. 2017 Oct [accessed 2020 June 3]. https://www.who.int/immunization/sage/meetings/2017/october/3_FULL_PRIME_REPORT_2017Sep26.pdf?ua=1.
   Google Scholar
• Naucler P, Galanis I, Morfeldt E, Darenberg J, Ortqvist A, Henriques-Normark B. Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations. Clin Infect Dis. 2017;65(11):1780–89. doi:10.1093/cid/cix685.
   PubMed Web of Science ®Google Scholar
• Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684–89. doi:10.1016/j.vaccine.2015.04.005.
   PubMed Web of Science ®Google Scholar
• Gouvernement du Québec. Advice and prevention - pneumococcal conjugate vaccine. 2018 [accessed 2020 June 3]. https://www.quebec.ca/en/health/advice-and-prevention/vaccination/pneumococcal-conjugate-vaccine/.
   Google Scholar
• Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495–502. doi:10.1016/s0140-6736(06)69637-2.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378(9807):1962–73. doi:10.1016/s0140-6736(10)62225-8.
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, Santos JB, de Moraes JC. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2(6):464–71. doi:10.1016/s2213-2600(14)70060-8.
   PubMed Web of Science ®Google Scholar
• Rinta-Kokko H, Auranen K, Toropainen M, Nuorti JP, Nohynek H, Siira L, Palmu AA. Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland. Vaccine. 2020;38(6):1559–64. doi:10.1016/j.vaccine.2019.11.049.
   PubMed Web of Science ®Google Scholar
• Verani JR, Domingues CM, de Moraes JC. Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group. Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease. Vaccine. 2015;33(46):6145–48. doi:10.1016/j.vaccine.2015.10.007.
   PubMed Web of Science ®Google Scholar
• Riaz A, Mohiuddin S, Husain S, Yousafzai MT, Sajid M, Kabir F, Rehman NU, Mirza W, Salam B, Nadeem N, et al. Effectiveness of 10-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in Pakistan. Int J Infect Dis. 2019;80:28–33. doi:10.1016/j.ijid.2018.12.007.
   PubMed Web of Science ®Google Scholar
• Berman-Rosa M, O’Donnell S, Barker M, Quach C. Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease. Pediatrics. 2020;145(4):e20190377. doi:10.1542/peds.2019-0377.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46. doi:10.1016/s1473-3099(14)70822-9.
   PubMed Web of Science ®Google Scholar
• Weinberger R, van der Linden M, Imohl M, von Kries R. Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule. Vaccine. 2016;34(18):2062–65. doi:10.1016/j.vaccine.2016.02.043.
   PubMed Web of Science ®Google Scholar
• Cohen C, von Mollendorf C, de Gouveia L, Lengana S, Meiring S, Quan V, Nguweneza A, Moore DP, Reubenson G, Moshe M, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study. Lancet Glob Health. 2017;5(3):e359–e369. doi:10.1016/s2214-109x(17)30043-8.
   PubMed Web of Science ®Google Scholar
• Dominguez A, Ciruela P, Hernandez S, Garcia-Garcia JJ, Soldevila N, Izquierdo C, Moraga-Llop F, Diaz A, de Sevilla MF, Gonzalez-Peris S, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. PLoS One. 2017;12(8):e0183191. doi:10.1371/journal.pone.0183191.
   PubMed Web of Science ®Google Scholar
• Gidding HF, McCallum L, Fathima P, Moore HC, Snelling TL, Blyth CC, Jayasinghe S, Giele C, de Klerk N, Andrews RM, et al. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia. Vaccine. 2018;36(19):2650–56. doi:10.1016/j.vaccine.2018.03.058.
   PubMed Web of Science ®Google Scholar
• Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study. Clin Infect Dis. 2018;67(3):367–74. doi:10.1093/cid/ciy129.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, Scherzinger K, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4(5):399–406. doi:10.1016/s2213-2600(16)00052-7.
   PubMed Web of Science ®Google Scholar
• van der Linden M, Falkenhorst G, Perniciaro S, Fitzner C, Imohl M. Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany. PLoS One. 2016;11(8):e0161257. doi:10.1371/journal.pone.0161257.
   PubMed Web of Science ®Google Scholar
• Guevara M, Barricarte A, Torroba L, Herranz M, Gil-Setas A, Gil F, Bernaola E, Ezpeleta C, Castilla J. Working Group for Surveillance of the Pneumococcal Invasive Disease in Navarra. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study. Euro Surveill. 2016;21(14). doi:10.2807/1560-7917.Es.2016.21.14.30186.
   PubMedGoogle Scholar
• Tomczyk S, Lessa FC, Sanchez J, Peña C, Fernandez J, Gloria Carvalho M, Pimenta F, Cedano D, Whitney CG, Verani JR, et al. Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic. BMC Infect Dis. 2018;18(1):152. doi:10.1186/s12879-018-3047-3.
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381(9862):214–22. doi:10.1016/s0140-6736(12)61854-6.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11(6):e1001657. doi:10.1371/journal.pmed.1001657.
   PubMed Web of Science ®Google Scholar
• Andrews N, Kent A, Amin-Chowdhury Z, Sheppard C, Fry N, Ramsay M, Ladhani SN. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006-2018. Vaccine. 2019;37(32):4491–98. doi:10.1016/j.vaccine.2019.06.071.
   PubMed Web of Science ®Google Scholar
• Linley E, Bell A, Gritzfeld JF, Borrow R. Should pneumococcal serotype 3 be included in serotype-specific immunoassays? Vaccines (Basel). 2019;7(1):4. doi:10.3390/vaccines7010004.
   Web of Science ®Google Scholar
• Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 2011;10(3):307–22. doi:10.1586/erv.11.8.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hanage WP. Interim results of an ecological experiment - conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother. 2016;12(2):358–74. doi:10.1080/21645515.2015.1118593.
   PubMed Web of Science ®Google Scholar
• Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution. Expert Rev Vaccines. 2018;17(6):479–93. doi:10.1080/14760584.2018.1413354.
   PubMed Web of Science ®Google Scholar
• Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113. doi:10.1371/journal.pone.0177113.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–51. doi:10.1016/s1473-3099(18)30052-5.
   PubMed Web of Science ®Google Scholar
• Hernandez S, Moraga-Llop F, Diaz A, de Sevilla MF, Ciruela P, Muñoz-Almagro C, Codina G, Campins M, Garcia-Garcia JJ, Esteva C, et al. Failures of 13-valent conjugated pneumococcal vaccine in age-appropriately vaccinated children 2-59 months of age, Spain. Emerg Infect Dis. 2020;26(6):1147–55. doi:10.3201/eid2606.190951.
   PubMed Web of Science ®Google Scholar
• Oligbu G, Collins S, Andrews N, Sheppard CL, Fry NK, Slack MPE, Borrow R, Ladhani SN. Characteristics and serotype distribution of childhood cases of invasive pneumococcal disease following pneumococcal conjugate vaccination in England and Wales, 2006-2014. Clin Infect Dis. 2017;65(7):1191–98. doi:10.1093/cid/cix418.
   PubMed Web of Science ®Google Scholar
• Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines. 2009;8(11):1479–500. doi:10.1586/erv.09.113.
   PubMed Web of Science ®Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, Virolainen-Julkunen A, Toropainen M, Nuorti JP. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children – a population-based study. PLoS One. 2015;10(3):e0120290. doi:10.1371/journal.pone.0120290.
   PubMed Web of Science ®Google Scholar
• Rinta-Kokko H, Palmu AA, Auranen K, Nuorti JP, Toropainen M, Siira L, Virtanen MJ, Nohynek H, Jokinen J. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine. 2018;36(15):1934–40. doi:10.1016/j.vaccine.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Grant LR, O’Brien SE, Burbidge P, Haston M, Zancolli M, Cowell L, Johnson M, Weatherholtz RC, Reid R, Santosham M, et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One. 2013;8(9):e74906. doi:10.1371/journal.pone.0074906.
   PubMed Web of Science ®Google Scholar
• Su WJ, Lo HY, Chang CH, Chang LY, Chiu CH, Lee PI, Lu CY, Hsieh YC, Lai MS, Lin TY. Effectiveness of pneumococcal conjugate vaccines of different valences against invasive pneumococcal disease among children in Taiwan: a nationwide study. Pediatr Infect Dis J. 2016;35(4):e124–133. doi:10.1097/inf.0000000000001054.
   PubMed Web of Science ®Google Scholar
• Nieto Guevara J, Izurieta P, Hoet B. Response to: pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A? Expert Rev Vaccines. 2018;17(4):283–84. doi:10.1080/14760584.2018.1459247.
   PubMed Web of Science ®Google Scholar
• Kandasamy R, Voysey M, Collins S, Berbers G, Robinson H, Noel I, Hughes H, Ndimah S, Gould K, Fry N, et al. Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom. J Infect Dis. 2020;221(8):1361–70. doi:10.1093/infdis/jiz178.
   PubMed Web of Science ®Google Scholar
• Desmet S, Lagrou K, Wyndham-Thomas C, Braeye T, Verhaegen J, Maes P, Fieuws S, Peetermans WE, Blumental S. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study. Lancet Infect Dis. 2020;21:127–36. doi:10.1016/s1473-3099(20)30173-0.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hoet B, Adegbola RA. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough. Expert Rev Vaccines. 2015;14(3):413–28. doi:10.1586/14760584.2015.965160.
   PubMed Web of Science ®Google Scholar
• Abu Seir R, Azmi K, Hamdan A, Namouz H, Jaar F, Jaber H, Rubin C, Doron D, Rahav G, Abdeen Z, et al. Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collaborative Research (PICR). PLoS One. 2018;13(11):e0206927. doi:10.1371/journal.pone.0206927.
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Etyang AO, Morpeth SC, Ojal J, Mutuku A, Mturi N, Moisi JC, Adetifa IM, Karani A, Akech DO, et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet. 2019;393(10186):2146–54. doi:10.1016/s0140-6736(18)33005-8.
   PubMed Web of Science ®Google Scholar
• Southern J, Andrews N, Sandu P, Sheppard CL, Waight PA, Fry NK, Van Hoek AJ, Miller E. Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England. PLoS One. 2018;13(5):e0195799. doi:10.1371/journal.pone.0195799.
   PubMed Web of Science ®Google Scholar
• Usuf E, Bottomley C, Bojang E, Cox I, Bojang A, Gladstone R, Kampmann B, Hill PC, Roca A. Persistence of nasopharyngeal pneumococcal vaccine serotypes and increase of nonvaccine serotypes among vaccinated infants and their mothers 5 years after introduction of pneumococcal conjugate vaccine 13 in The Gambia. Clin Infect Dis. 2019;68(9):1512–21. doi:10.1093/cid/ciy726.
   PubMed Web of Science ®Google Scholar
• Vissers M, Wijmenga-Monsuur AJ, Knol MJ, Badoux P, van Houten MA, van der Ende A, Sanders EAM, Rots NY. Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands. PLoS One. 2018;13(3):e0194823. doi:10.1371/journal.pone.0194823.
   PubMed Web of Science ®Google Scholar
• Odutola A, Ota MOC, Antonio M, Ogundare EO, Saidu Y, Foster-Nyarko E, Owiafe PK, Ceesay F, Worwui A, Idoko OT, et al. Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: a phase 2, randomized, controlled, observer-blind study. Vaccine. 2017;35(19):2531–42. doi:10.1016/j.vaccine.2017.03.071.
   PubMed Web of Science ®Google Scholar
• Pomat WS, van den Biggelaar AHJ, Wana S, Francis JP, Solomon V, Greenhill AR, Ford R, Orami T, Passey M, Jacoby P, et al. Safety and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: a randomized controlled trial of 10-valent and 13-valent pneumococcal conjugate vaccine in Papua New Guinean infants. Clin Infect Dis. 2019;68(9):1472–81. doi:10.1093/cid/ciy743.
   PubMed Web of Science ®Google Scholar
• de Oliveira LH, Shioda K, Valenzuela MT, Janusz CB, Rearte A, Sbarra AN, Warren JL, Toscano CM, Weinberger DM, Multinational Study for PCV Impact in Mortality Study Team. Declines in pneumonia mortality following the introduction of pneumococcal conjugate vaccines in Latin American and Caribbean countries. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa614.
   Google Scholar
• Gisselsson-Solen M. Trends in otitis media incidence after conjugate pneumococcal vaccination: a national observational study. Pediatr Infect Dis J. 2017;36(11):1027–31. doi:10.1097/inf.0000000000001654.
   PubMed Web of Science ®Google Scholar
• Edmondson-Jones M, Dibbern T, Hultberg M, Anell B, Medin E, Feng Y, Talarico C. The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions. Hum Vaccin Immunother. 2020;1–10. doi:10.1080/21645515.2020.1775455.
   PubMedGoogle Scholar